Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study.

The lancet. Diabetes & endocrinology·2017
Same author

The association of lipoprotein(a) with incident heart failure hospitalization: Atherosclerosis Risk in Communities study.

Atherosclerosis·2017
Same author

Serum vitamin D and change in lipid levels over 5 y: The Atherosclerosis Risk in Communities study.

Nutrition (Burbank, Los Angeles County, Calif.)·2017
Same author

A simplified pathway to proprotein convertase subtilisin/kexin type 9 inhibitor prior authorization approval: A lipid clinic experience.

Journal of clinical lipidology·2017
Same author

The Upregulation of Integrin α<sub>D</sub>β<sub>2</sub> (CD11d/CD18) on Inflammatory Macrophages Promotes Macrophage Retention in Vascular Lesions and Development of Atherosclerosis.

Journal of immunology (Baltimore, Md. : 1950)·2017
Same author

Dyslipidaemia: PCSK9 inhibitors and foamy monocytes in familial hypercholesterolaemia.

Nature reviews. Cardiology·2017
Same journal

Clinical pharmacokinetics of colistimethate sodium and formed colistin in patients with renal impairment or on dialysis modalities: a systematic review and implications for precision dosing.

Postgraduate medicine·2026
Same journal

The role of type D personality in pregnancy symptom severity, functional limitations, and maternal ambivalence.

Postgraduate medicine·2026
Same journal

Operational and demographic predictors of leaving without being seen in a high-volume tertiary emergency department: a five-year case-control study.

Postgraduate medicine·2026
Same journal

Risk of adverse effects of the concomitant use of statins with calcium channel blockers: a systematic review and meta-analysis.

Postgraduate medicine·2026
Same journal

Association between frailty and major chronic disease-free life expectancy: a large community-based longitudinal study.

Postgraduate medicine·2026
Same journal

The prevalence of functional iron deficiency and its impact on mortality in patients receiving hemodialysis.

Postgraduate medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 14, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Strategies for optimizing lipid management.

Christie M Ballantyne1

  • 1Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Baylor College of Medicine, Houston, TX 77030, USA. cmb@bcm.tmc.edu

Postgraduate Medicine
|August 12, 2009
PubMed
Summary
This summary is machine-generated.

Lipid measures beyond LDL-C, like non-HDL-C and apo B, may better predict cardiovascular risk. Achieving optimal levels of these atherogenic lipoproteins is crucial for reducing residual risk despite statin therapy.

More Related Videos

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

A Workflow for Lipid Nanoparticle (LNP) Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models (SVEM)
13:54

A Workflow for Lipid Nanoparticle (LNP) Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models (SVEM)

Published on: August 18, 2023

Related Experiment Videos

Last Updated: Jun 14, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

A Workflow for Lipid Nanoparticle (LNP) Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models (SVEM)
13:54

A Workflow for Lipid Nanoparticle (LNP) Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models (SVEM)

Published on: August 18, 2023

Area of Science:

  • Cardiology
  • Lipidology
  • Preventive Medicine

Background:

  • Current low-density lipoprotein cholesterol (LDL-C) goals for high-risk patients are < 100 mg/dL, with some suggesting < 70 mg/dL.
  • Residual cardiovascular risk persists despite current lipid-lowering therapies.
  • Lipid measures beyond LDL-C may offer superior cardiovascular risk prediction.

Purpose of the Study:

  • To evaluate the utility of non-high-density lipoprotein cholesterol (non-HDL-C) and apolipoprotein B (apo B) in cardiovascular risk assessment.
  • To determine if current lipid-lowering therapies achieve optimal levels of atherogenic lipoproteins.
  • To identify optimal lipid targets for reducing residual cardiovascular risk.

Main Methods:

  • Analysis of existing evidence on lipid measures and cardiovascular risk.
  • Comparison of non-HDL-C and LDL-C in predicting cardiovascular events.
  • Assessment of apo B and apo B/apo A-I ratio as predictors of risk on statin therapy.

Main Results:

  • Non-HDL-C is superior to LDL-C in predicting cardiovascular risk.
  • Apo B levels and apo B/apo A-I ratio are strong predictors of acute vascular events.
  • Optimal apo B levels may not be achieved with intensive statin therapy.

Conclusions:

  • Non-HDL-C and apo B are valuable tools for cardiovascular risk assessment and guiding therapy.
  • Achieving optimal targets for non-HDL-C and apo B is essential for reducing residual cardiovascular risk.
  • Further research and efforts are needed to identify and achieve optimal lipid targets.